Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T11:08:31.290Z Has data issue: false hasContentIssue false
  • English
  • Français

Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease

Published online by Cambridge University Press:  07 November 2014

James W. Tetrud
Get access Rights & Permissions [Opens in a new window]

Abstract

Levodopa has played a central role in the treatment of Parkinson's disease for nearly 40 years and remains the single most effective symptomatic treatment for the disease. However, the response to levodopa therapy changes over time, and its long-term use is commonly associated with disabling motor complications. For this reason, the appropriate role of levodopa in the treatment of Parkinson's disease—in particular, the question of when to initiate therapy with the drug—has been a matter of controversy. Because levodopa is the most effective treatment for Parkinson's disease, the management of this disease becomes a matter of balancing short-term symptom control with long-term functional outcomes. This article provides an overview of the basis for levodopa-associated motor complications and their impact on patients' clinical function and quality of life, followed by a discussion of strategies for managing these complications to achieve optimum symptom control while minimizing the adverse effects of long-term therapy.

Type
Review Article
Information
CNS Spectrums , Volume 12 , Issue 4 , April 2007 , pp. 275 - 286
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. National Center for Health Statistics. NCHS data on Parkinson's disease. Available at: http://www.cdc.gov/nchs/data/factsheets/Parkinsons.pdf. 2005. Accessed on July 19, 2006.Google Scholar
2.Tanner, CM, Aston, DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol. 2000;13:427–430.CrossRefGoogle ScholarPubMed
3.Lang, AE, Lozano, AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339:1044–1053.CrossRefGoogle ScholarPubMed
4.Guttman, M, Kish, SJ, Furukawa, Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ. 2003;168:293–301.Google ScholarPubMed
5.Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211.CrossRefGoogle ScholarPubMed
6.Colcher, A, Simuni, T. Clinical manifestations of Parkinson's disease. Med Clin North Am. 1999;83:327–347.CrossRefGoogle ScholarPubMed
7.Dhawan, V, Healy, DG, Pal, S, Chaudhuri, KR. Sleep-related problems of Parkinson's disease. Age Aging. 2006;35:220–228.CrossRefGoogle ScholarPubMed
8.Koller, WC, Tse, W. Unmet medical needs in Parkinson's disease. Neurology. 2004;62(suppl 1):S1–S8.CrossRefGoogle ScholarPubMed
9.Rascol, O, Goetz, C, Koller, W, Poewe, W, Sampaio, C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002;359:1589–1598.CrossRefGoogle ScholarPubMed
10.Hoehn, MM, Yahr, MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.CrossRefGoogle ScholarPubMed
11.Koller, W, Guarnieri, M, Hubble, J, Rabinowicz, AL, Silver, D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 2005;112:221–230.CrossRefGoogle ScholarPubMed
12.Cohen, G, Spina, MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989;26:689–690.CrossRefGoogle ScholarPubMed
13.Schapira, AH, Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559–562.CrossRefGoogle ScholarPubMed
14.Aminoff, MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neurol. 2006;59:562–564.CrossRefGoogle Scholar
15.Fahn, S, Oakes, D, Shoulson, I, et al.Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498–2508.Google ScholarPubMed
16.Thanvi, BR, Lo, TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J. 2004;80:452–458.CrossRefGoogle ScholarPubMed
17.Adler, CH. Relevance of motor complications in Parkinson's disease. Neurology. 2002;58(suppl 1):S51–S56.CrossRefGoogle ScholarPubMed
18.Muller, T, Russ, H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother. 2006;7:1715–1730.CrossRefGoogle ScholarPubMed
19.Sato, K, Hatano, T, Yamashiro, K, et al.Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:1384–1395.CrossRefGoogle Scholar
20.Schrag, A, Quinn, N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000;123(pt 11):2297–2305.CrossRefGoogle ScholarPubMed
21.Mazzella, L, Yahr, MD, Marinelli, L, Huang, N, Moshier, E, Di Rocco, A. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy. Parkinsonism Relat Disord. 2005;11:151–155.CrossRefGoogle ScholarPubMed
22.Mccoll, CD, Reardon, KA, Shiff, M, Kempster, PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord. 2002;17:1227–1234.CrossRefGoogle ScholarPubMed
23.Rajput, AH, Fenton, ME, Birdi, S, et al.Clinical-pathological study of levodopa complications. Mov Disord. 2002;17:289–296.CrossRefGoogle ScholarPubMed
24.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson's deseaseclinical aspects. In: Marsden, CD, Fahn, S, eds. Movement Disorders. Boston, Mass: Butterworth Scientific; 1982;96–122.Google Scholar
25.Ahlskog, JE, Muenter, MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458.CrossRefGoogle ScholarPubMed
26.Blanchet, PJ, Allard, P, Gregoire, L, Tardif, F, Bedard, PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189–193.CrossRefGoogle ScholarPubMed
27.Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931–1938.CrossRefGoogle Scholar
28.Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39:37–45.Google Scholar
29.Stacy, M, Bowron, A, Guttman, M, et al.Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005;20:726–733.CrossRefGoogle ScholarPubMed
30.Nutt, JG, Woodward, WR, Carter, JH, Gancher, ST. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol. 1992;49:1123–1130.CrossRefGoogle Scholar
31.Barbato, L, Stocchi, F, Monge, A, et al.The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. 1997;20:394–401.CrossRefGoogle ScholarPubMed
32.Nutt, JG, Carter, JH, Lea, ES, Sexton, GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002;51:686–693.CrossRefGoogle ScholarPubMed
33.Obeso, JA, Rodriguez-Oroz, M, Marin, C, et al.The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology. 2004;62(suppl 1):S17–S30.CrossRefGoogle ScholarPubMed
34.Metman, LV, Konitsiotis, S, Chase, TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000;15:3–8.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
35.Olanow, CW, Obeso, JA, Stocchi, F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–687.CrossRefGoogle ScholarPubMed
36.Chapuis, S, Ouchchane, L, Metz, O, Gerbaud, L, Durif, F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224–230.CrossRefGoogle ScholarPubMed
37.Wilson, RE, Silver, D, Spears, JB, Van Lunen, BE. Implications of motor fluctuations in Parkinson's patients on chronic therapy (IMPACT) registry: quality of life (QOL) data. Mov Disord. 2006;21(suppl 1):S151.Google Scholar
38.Bloem, BR, Hausdorff, JM, Visser, JE, Giladi, N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord. 2004;19:871–884.CrossRefGoogle ScholarPubMed
39.Martinez-Martin, P, Benito-Leon, J, Alonso, F, et al.Quality of life of caregivers in Parkinson's disease. Qual Life Res. 2005;14:463–472.CrossRefGoogle ScholarPubMed
40.Witjas, T, Kaphan, E, Azulay, JP, et al.Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology. 2002;59:408–413.CrossRefGoogle ScholarPubMed
41.van Laar, T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs. 2003;17:475–489.CrossRefGoogle ScholarPubMed
42. Parcopa [package insert]. Milwaukee, Wis: Schwarz Pharma; 2006.Google Scholar
43. Sinemet [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.Google Scholar
44. Sinemet CR [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2002.Google Scholar
45. Stalevo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2004.Google Scholar
46. Apokyn [package insert]. Research Triangle Park, NC: Mylan Bertek Pharmaceuticals, Inc.; 2004.Google Scholar
47. Parlodel Snap Tabs [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.Google Scholar
48. Permax [package insert]. Indianapolis, Ind: Eli Lilly & Co.; 2001.Google Scholar
49. Mirapex [package insert]. Ridgefield, Conn: Boehringer-Ingelheim International GmbH; 2006.Google Scholar
50. Requip [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.Google Scholar
51. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2000.Google Scholar
52. Tasmar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.Google Scholar
53. Azilect [package insert]. Kansas City, Mo: Teva Pharmaceutical Industries, Ltd.; 2006.Google Scholar
54. Eldepryl [package insert]. Tampa, Fla: Somerset Pharmaceuticals; 1998.Google Scholar
55. Zelapar [package insert]. Costa Mesa, Calif: Valeant Pharmaceuticals International; 2006.Google Scholar
56. Symadine [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp.; 2006.Google Scholar
57. Symmetrel [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; 2002.Google Scholar
58. Cogentin [package insert]. Whitehouse Station, NJ; Merck & Co., Inc.; 2006.Google Scholar
59. Artane [package insert]. Pearl River, NY: Lederle Pharmaceutical Division; 2003.Google Scholar
60.Grosset, KA, Bone, I, Grosset, DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20:1502–1507.CrossRefGoogle ScholarPubMed
61.Koller, WC, Hutton, JT, Tolosa, E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53:1012–1019.CrossRefGoogle ScholarPubMed
62.Olanow, CW, Watts, RL, Koller, WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1–S88.CrossRefGoogle ScholarPubMed
63.Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168.CrossRefGoogle ScholarPubMed
64.LeWitt, PA, Chang, F-L, Fazzini, E, Nausieda, PA, Daniel, T, Boroojerdi, B. Rotigotine transdermal system in treatment of patients with advanced-stage Parkinson's disease. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 17-20, 2005; Athens, Greece.Google Scholar
65.Poewe, W, Giladi, N, Maguire, D, Boroojerdi B. Rotigotine transdermal patch in patients with parkinson's disease and motor fluctuations. 24H symptom control in a placebo- and Pramipexole-controlled, randomized, double-blind, double dummy trial. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.Google Scholar
66.Pahwa, R, Factor, SA, Elmer, LW. Ropinirole 24-hour prolonged release reduces ‘off’ time in patients with parkinson's disease not optimally controlled with L-Dopa. Abstract presented at: annual meeting of European Federation of Neurological Societies Congress. September 2-5, 2006; Glasgow, Scotland.Google Scholar
67.Dodd, ML, Klos, KJ, Bower, JH, Geda, YE, Josephs, KA, Ahlskog, JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377–1381.CrossRefGoogle ScholarPubMed
68.Watts, RL, Jankovic, J, Waters, C, Rajput, A, Boroojerdi, B, Rao, J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276.CrossRefGoogle ScholarPubMed
69.Avorn, J, Schneeweiss, S, Sudarsky, LR, et al.Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005;62:1242–1248.CrossRefGoogle ScholarPubMed
70.Pezzella, FR, Colosimo, C, Vanacore, N, et al.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord. 2005;20:77–81.CrossRefGoogle ScholarPubMed
71.Pontone, G, Williams, JR, Bassett, SS, Marsh, L. Clinical features associated with impulse control disorders in Parkinson disease. Neurology. 2006;67:1258–1261.CrossRefGoogle ScholarPubMed
72.Sundberg, S, Scheinin, M, Illi, A, Akkila, J, Gordin, A, Keranen, T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 1993;36:451–456.CrossRefGoogle ScholarPubMed
73.Zanettini, R, Antonini, A, Gatto, G, Gentile, R, Tesei, S, Pezzoli, G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39–46.CrossRefGoogle ScholarPubMed
74.Van Camp, G, Flamez, A, Cosyns, B, et al.Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179–1183.CrossRefGoogle ScholarPubMed
75.Horvath, J, Fross, RD, Kleiner-Fisman, G, et al.Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656–662.CrossRefGoogle ScholarPubMed
76.Waters, CH, Sethi, KD, Hauser, RA, Molho, E, Bertoni, JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426–432.CrossRefGoogle ScholarPubMed
77.Stocchi, F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract. 2006;60:215–221.CrossRefGoogle ScholarPubMed
78.Rascol, O, Brooks, DJ, Melamed, E, et al.Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947–954CrossRefGoogle ScholarPubMed
79.Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–248.CrossRefGoogle Scholar
80.Goetz, CG, Poewe, W, Rascol, O, Sampaio, C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005;20:523–539.CrossRefGoogle ScholarPubMed
81.Thomas, A, lacono, D, Luciano, AL, Armellino, K, Di Iorio, A, Onofrj, M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75:141–143.Google ScholarPubMed
82.Luginger, E, Wenning, GK, Bosch, S, Poewe, W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15:873–878.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
83.Weller, M, Kornhuber, J. Amantadine withdrawal and neuroleptic malignant syndrome. Neurology. 1993;43:2155.Google ScholarPubMed
84.Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord. 2002;17(suppl 4):S7–S12.CrossRefGoogle Scholar
85.Katzenschlager, R, Sampaio, C, Costa, J, Lees, A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;CD003735.Google Scholar
86.Stocchi, F, Olanow, CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology. 2004;62(suppl 1):S56–S63.CrossRefGoogle ScholarPubMed
87.Adler, CH, Singer, C, O'Brien, C, et al.Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55:1089–1095.CrossRefGoogle ScholarPubMed
88.Borges, N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26:743–747.CrossRefGoogle ScholarPubMed
89.Hauser, RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology. 2004;62(suppl 1):S64–S71.CrossRefGoogle ScholarPubMed
90.Stocchi, F, Vacca, L, Grassini, P, et al.Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci. 2003;24:217–218.CrossRefGoogle ScholarPubMed
91.Parkinson Study Group. Entacapone improves motor fluctuations in levodopatreated Parkinson's disease patients. Ann Neurol. 1997;42:747–755.CrossRefGoogle Scholar
92.Rinne, UK, Larsen, JP, Siden, A, Worm-Petersen, J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998;51:1309–1314.CrossRefGoogle ScholarPubMed
93.Poewe, WH, Deuschl, G, Gordin, A, Kultalahti, E-R, Leinonen, M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–255.CrossRefGoogle ScholarPubMed
94.Reichmann, H, Boas, J, Macmahon, D, Myllyla, V, Hakala, A, Reinikainen, K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. 2005;111:21–28.CrossRefGoogle ScholarPubMed
95.Brooks, DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(suppl 1):S39–S46.CrossRefGoogle ScholarPubMed
96.Silver, DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). Expert Rev Neurother. 2004;4:589–599.CrossRefGoogle ScholarPubMed
97.Brooks, DJ, Agid, Y, Eggert, K, Widner, H, Ostergaard, K, Holopainen, A; TC-INIT Study Group. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53:197–202.CrossRefGoogle Scholar
98.Myllyla, V, Haapaniemi, T, Kaakkola, S, et al.Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol Scand. 2006;114:181–186.CrossRefGoogle ScholarPubMed
99.Dewey, RB Jr, Hutton, JT, LeWitt, PA, Factor, SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–1392.CrossRefGoogle ScholarPubMed
100.Zijlmans, JC, Debilly, B, Rascol, O, Lees, AJ, Durif, F. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord. 2004;19:1006–1011.CrossRefGoogle ScholarPubMed
101.Pahwa, R, Factor, SA, Lyons, KE, et al.Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–985.CrossRefGoogle Scholar